Are Peptides Legal in Virginia? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Virginia as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Virginia attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Virginia statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Virginia has scheduled or banned on its own. The Virginia Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Virginia at a glance

State controlled-substances law: Virginia Drug Control Act, Va. Code Title 54.1, Ch. 34 (§ 54.1-3400 et seq.); controlled substance schedules in Article 5 (§§ 54.1-3443 to 54.1-3456.1); Schedule III at § 54.1-3450 (law.lis.virginia.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Va. Code § 54.1-3450 (Schedule III) and Article 5 generally; § 18.2-248.5) (law.lis.virginia.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No Virginia Board of Pharmacy guidance specific to semaglutide, tirzepatide or peptides. The Board's compounding guidance (document 110-36, effective 6 June 2024) requires compliance with USP 795, 797 and 800, allows only nonresident pharmacies and outsourcing facilities registered with the Virginia Board to ship compounded sterile products into Virginia, and limits distribution of compounded products to prescribers to emergency use or as federal law allows. It does not mention semaglutide, GLP-1s or 503A copies (2024-06-06) (dhp.virginia.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Va. Code § 54.1-3303 requires a bona fide practitioner-patient relationship before any prescription: a medical history, a discussion of benefits and risks, an appropriate examination (in person or by diagnostic equipment) and follow-up. The relationship may be established by telemedicine when those conditions are met and the prescriber holds a Virginia licence. Board of Medicine guidance 85-12 adds that a prescription based solely on an online questionnaire does not meet the standard of care. GLP-1 pens are prescribable by a Virginia-licensed telehealth prescriber on that basis. (law.lis.virginia.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Virginia, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Virginia:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Virginia. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Virginia law adds

Virginia's controlled-substances law (Virginia Drug Control Act, Va. Code Title 54.1, Ch. 34 (§ 54.1-3400 et seq.); controlled substance schedules in Article 5 (§§ 54.1-3443 to 54.1-3456.1); Schedule III at § 54.1-3450) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (law.lis.virginia.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Virginia's schedules or in a Virginia-specific ban as of September 2026. That is the position in most states.

Human growth hormone

The full text of § 54.1-3450 and the rest of Article 5 (Schedules I to VI) contains no mention of growth hormone, somatropin or any peptide; subsection 6 covers anabolic steroids only, and § 18.2-248.5 criminalises anabolic steroids and caffeine or ephedrine combinations without mentioning HGH. HGH is not a Virginia-scheduled substance; the federal statute applies. (Va. Code § 54.1-3450 (Schedule III) and Article 5 generally; § 18.2-248.5) (law.lis.virginia.gov)

Compounded semaglutide and tirzepatide

2024-06-06. No Virginia Board of Pharmacy guidance specific to semaglutide, tirzepatide or peptides. The Board's compounding guidance (document 110-36, effective 6 June 2024) requires compliance with USP 795, 797 and 800, allows only nonresident pharmacies and outsourcing facilities registered with the Virginia Board to ship compounded sterile products into Virginia, and limits distribution of compounded products to prescribers to emergency use or as federal law allows. It does not mention semaglutide, GLP-1s or 503A copies. (dhp.virginia.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Virginia medical board guidance specific to peptide therapy was located. A Virginia prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Virginia

Virginia has no possession provision specific to HGH or research peptides because neither is on the state schedules; simple possession of a Schedule III substance such as an anabolic steroid is a Class 1 misdemeanor under Va. Code § 18.2-250, and otherwise the federal rules apply. (law.lis.virginia.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Virginia is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Va. Code § 54.1-3303 requires a bona fide practitioner-patient relationship before any prescription: a medical history, a discussion of benefits and risks, an appropriate examination (in person or by diagnostic equipment) and follow-up. The relationship may be established by telemedicine when those conditions are met and the prescriber holds a Virginia licence. Board of Medicine guidance 85-12 adds that a prescription based solely on an online questionnaire does not meet the standard of care. GLP-1 pens are prescribable by a Virginia-licensed telehealth prescriber on that basis. (law.lis.virginia.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Virginia law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Virginia

2025-02-19. Virginia Attorney General Jason Miyares signed the bipartisan letter of 38 state and territory attorneys general urging the FDA to act against counterfeit GLP-1 drugs and against online sellers offering semaglutide and tirzepatide labelled for research purposes only. No Virginia-specific enforcement action on peptides or GLP-1s was found. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. A 2026 session bill, HB917, appeared in search results as adding restrictions on bulk drug substances in compounding (withdrawn drugs, unapproved substances, essentially copies of commercial drugs); its text and status could not be opened and are unverified. No Board of Medicine statement on peptides or BPC-157 was found.

Frequently asked questions

Is BPC-157 legal in Virginia?

Virginia has not scheduled BPC-157, so possessing it is not a Virginia offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Virginia?

Va. Code § 54.1-3303 requires a bona fide practitioner-patient relationship before any prescription: a medical history, a discussion of benefits and risks, an appropriate examination (in person or by diagnostic equipment) and follow-up. The relationship may be established by telemedicine when those conditions are met and the prescriber holds a Virginia licence. Board of Medicine guidance 85-12 adds that a prescription based solely on an online questionnaire does not meet the standard of care. GLP-1 pens are prescribable by a Virginia-licensed telehealth prescriber on that basis. The Virginia Board of Pharmacy position on compounded versions: No Virginia Board of Pharmacy guidance specific to semaglutide, tirzepatide or peptides. The Board's compounding guidance (document 110-36, effective 6 June 2024) requires compliance with USP 795, 797 and 800, allows only nonresident pharmacies and outsourcing facilities registered with the Virginia Board to ship compounded sterile products into Virginia, and limits distribution of compounded products to prescribers to emergency use or as federal law allows. It does not mention semaglutide, GLP-1s or 503A copies.

Is HGH legal in Virginia?

Only with a valid prescription for an approved use. Virginia does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Virginia fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.